NKX2-8 and ovarian carcinoma: Nonetheless, in epithelial ovarian cancer, the developmental regulator NKX2-8 is able to transcriptionally inhibit CPT2 by recruiting the transcriptional repressor complex Sin3A/HDAC1/SAP18, and the combination of pegfilgrastim and platinum drugs enhances therapeutic effects in epithelial ovarian cancer [11].